Advertisement

Hepatology International

, Volume 13, Issue 4, pp 391–394 | Cite as

New treatment-induced adverse effects we need to learn as modern hepatologists

  • Yoshiyuki UenoEmail author
Invited Commentary
  • 108 Downloads

In this issue, Nishida and Kudo have written a review article entitled, “Liver damage related to immune check point inhibitors.” [1]. As we know, any medical treatment, whether medical or surgical, can exert an adverse effect at any level. Classically, for example, in the field of hepatology, it is well known that microvesicular steatosis is related to the administration of aspirin, resulting in so-called Rye’s syndrome, of which the essential pathogenesis is mitochondria damage in the hepatocytes. In the age of interferon, the hypothyroidism induced by interferon administration is a well-known iatrogenic disease that frequently needs medical treatment. Moreover, even liver transplantation is consistently required for drug-induced acute liver failure worldwide. Most recently, molecular targeting drugs also induce varieties of hepatic injury while treating hepatocellular carcinoma (HCC) [2, 3]. Thus, sometimes it is ironical that we may induce new diseases during treatment in patients...

Keywords

Immune check point inhibitor Liver toxicity Molecular targetting drug PD-1 PD-L1 

Notes

References

  1. 1.
    Nishida N, Kudo M. Liver damage related to immune checkpoint inhibitors. Hepatol Int. 2019. https://doi.org/10.1007/s12072-018-9921-7
  2. 2.
    Ikeda K, Kudo M, Kawazoe S, Osaki Y, Ikeda M, Okusaka T, et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol 2017;52(4):512–519CrossRefPubMedGoogle Scholar
  3. 3.
    Kudo M, Hatano E, Ohkawa S, Fujii H, Masumoto A, Furuse J, et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial. J Gastroenterol 2017;52(4):494–503CrossRefPubMedGoogle Scholar
  4. 4.
    Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017;11(4):317–370CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Kudo M. Combination cancer immunotherapy in hepatocellular carcinoma. Liver Cancer 2018;7(1):20–27CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389(10088):2492–2502CrossRefPubMedGoogle Scholar
  7. 7.
    Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018;19(7):940–952CrossRefPubMedGoogle Scholar
  8. 8.
    Nadeau BA, Fecher LA, Owens SR, Razumilava N. Liver toxicity with cancer checkpoint inhibitor therapy. Semin Liver Dis 2018;38(4):366–378CrossRefPubMedGoogle Scholar
  9. 9.
    Parlati L, Vallet-Pichard A, Batista R, Hernvann A, Sogni P, Pol S, et al. Incidence of grade 3–4 liver injury under immune checkpoints inhibitors: a retrospective study. J Hepatol 2018;69(6):1396–1397CrossRefPubMedGoogle Scholar
  10. 10.
    Huffman BM, Kottschade LA, Kamath PS, Markovic SN. Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management. Am J Clin Oncol 2018;41(8):760–765CrossRefPubMedGoogle Scholar
  11. 11.
    Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol 2018;36(17):1714–1768CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Nishida N, Kudo M. Immune checkpoint blockade for the treatment of human hepatocellular carcinoma. Hepatol Res 2018;48(8):622–634CrossRefPubMedGoogle Scholar
  13. 13.
    De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol 2018;68(6):1181–1190CrossRefPubMedGoogle Scholar
  14. 14.
    Suzman DL, Pelosof L, Rosenberg A, Avigan MI. Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents. Liver Int 2018;38(6):976–987CrossRefGoogle Scholar

Copyright information

© Asian Pacific Association for the Study of the Liver 2019

Authors and Affiliations

  1. 1.Department of GastroenterologyFaculty of Medicine Yamagata UniversityYamagataJapan

Personalised recommendations